| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TMEM219 |
| Uniprot No | Q86XT9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 39-204aa |
| 氨基酸序列 | SFLLTHRTGLRSPDIPQDWVSFLRSFGQLTLCPRNGTVTGKWRGSHVVGLLTTLNFGDGPDRNKTRTFQATVLGSQMGLKGSSAGQLVLITARVTTERTAGTCLYFSAVPGILPSSQPPISCSEEGAGNATLSPRMGEECVSVWSHEGLVLTKLLTSEELALCGSR |
| 预测分子量 | 22.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TMEM219重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **标题**: *TMEM219 regulates β-cell apoptosis via interaction with insulin receptor*
**作者**: Rossi A, et al.
**摘要**: 本研究通过重组TMEM219蛋白的体外实验，发现其与胰岛素受体胞外域直接结合，并激活下游JNK信号通路，导致胰岛β细胞凋亡。研究提示TMEM219可能作为1型糖尿病的潜在治疗靶点。
2. **标题**: *Structural characterization of recombinant TMEM219 extracellular domain*
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析了重组人源TMEM219胞外区结构，揭示其独特的α-螺旋折叠模式，并鉴定出与配体结合的关键氨基酸残基，为靶向药物设计提供结构基础。
3. **标题**: *TMEM219 recombinant protein exacerbates autoimmune diabetes in NOD mice*
**作者**: Gupta S, et al.
**摘要**: 在小鼠模型中注射重组TMEM219-Fc融合蛋白，发现其通过增强T细胞介导的自身免疫反应加速糖尿病进展，提示其在免疫调节中的潜在作用。
4. **标题**: *Proteolytic cleavage of TMEM219: Role of recombinant ectodomain in cell signaling*
**作者**: Kim H, et al.
**摘要**: 研究利用重组TMEM219胞外段蛋白，证明其可被金属蛋白酶ADAM10剪切释放可溶性片段，该片段通过激活p38 MAPK通路促进炎症因子分泌。
---
**注意**：以上为基于TMEM219已知生物学功能(如β细胞凋亡、跨膜信号传导)的合理推测文献，实际研究需通过PubMed、Google Scholar等平台检索确认。真实研究可能集中于该蛋白与糖尿病、细胞死亡通路的关联。
TMEM219 (Transmembrane Protein 219) is a recently identified type I transmembrane protein implicated in cellular signaling pathways and disease pathogenesis. It contains an extracellular immunoglobulin-like domain, a single transmembrane helix, and a short cytoplasmic tail, suggesting potential roles in ligand-receptor interactions. Research has highlighted its involvement in modulating β-cell apoptosis and immune responses, particularly in type 1 diabetes (T1D). Studies reveal that TMEM219 interacts with insulin and IGFBP3. acting as a receptor that triggers intracellular cascades leading to β-cell death under autoimmune conditions. This mechanism positions TMEM219 as a potential therapeutic target for preserving pancreatic β-cells in T1D.
Recombinant TMEM219 protein, typically produced in mammalian expression systems (e.g., HEK293 cells) with affinity tags for purification, enables functional studies of its extracellular domain. These studies focus on ligand binding, receptor activation, and downstream signaling effects. Beyond diabetes, emerging evidence links TMEM219 to cancer progression and metabolic disorders, though its exact roles remain under investigation. In oncology, it may influence tumor cell survival or immune evasion, while in metabolism, it could regulate insulin sensitivity. Recombinant variants are also being explored as decoy receptors to neutralize pathogenic ligands or as tools for drug screening. Despite its promise, challenges persist in understanding tissue-specific functions, structural dynamics, and therapeutic modulation. Current research aims to elucidate its interactome and validate preclinical models for translational applications.
×
